Voya Investment Management LLC Has $103,000 Position in AngioDynamics, Inc. $ANGO

Voya Investment Management LLC cut its position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 14.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,985 shares of the medical instruments supplier’s stock after selling 1,930 shares during the quarter. Voya Investment Management LLC’s holdings in AngioDynamics were worth $103,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. ProShare Advisors LLC purchased a new stake in AngioDynamics in the 4th quarter valued at about $100,000. Squarepoint Ops LLC bought a new position in shares of AngioDynamics during the 4th quarter valued at $387,000. Public Employees Retirement System of Ohio grew its position in AngioDynamics by 5.8% during the 4th quarter. Public Employees Retirement System of Ohio now owns 70,972 shares of the medical instruments supplier’s stock worth $650,000 after acquiring an additional 3,900 shares during the last quarter. GAMMA Investing LLC raised its holdings in AngioDynamics by 1,281.4% in the 1st quarter. GAMMA Investing LLC now owns 13,897 shares of the medical instruments supplier’s stock worth $130,000 after purchasing an additional 12,891 shares in the last quarter. Finally, Acuitas Investments LLC raised its position in shares of AngioDynamics by 9.7% in the 1st quarter. Acuitas Investments LLC now owns 442,230 shares of the medical instruments supplier’s stock worth $4,153,000 after acquiring an additional 38,950 shares in the last quarter. 89.43% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of AngioDynamics in a research report on Wednesday, July 16th. Lake Street Capital started coverage on shares of AngioDynamics in a research report on Wednesday, July 16th. They issued a “buy” rating and a $24.00 price objective for the company. Canaccord Genuity Group upped their price target on shares of AngioDynamics from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Wednesday, July 16th. Finally, Wall Street Zen raised shares of AngioDynamics from a “hold” rating to a “buy” rating in a report on Saturday, August 16th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, AngioDynamics presently has an average rating of “Buy” and an average target price of $19.00.

AngioDynamics Stock Performance

Shares of ANGO opened at $11.07 on Thursday. AngioDynamics, Inc. has a 1 year low of $5.83 and a 1 year high of $13.50. The stock has a market capitalization of $454.76 million, a P/E ratio of -13.34 and a beta of 0.78. The company’s fifty day moving average is $9.84 and its two-hundred day moving average is $9.73.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Tuesday, July 15th. The medical instruments supplier reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.09. The firm had revenue of $80.16 million for the quarter, compared to analysts’ expectations of $74.26 million. AngioDynamics had a negative net margin of 11.62% and a negative return on equity of 3.20%. The firm’s revenue was up 13.0% on a year-over-year basis. During the same period in the prior year, the company earned ($0.06) EPS. AngioDynamics has set its FY 2026 guidance at -0.350–0.250 EPS. Sell-side analysts predict that AngioDynamics, Inc. will post -0.37 EPS for the current year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.